BCL2 and acute lymphoblastic leukemia: Conversely, targeting upstream components of the JAK/STAT pathway or directly interfering with the pro-survival BCL2 protein with small molecule inhibitors sensitizes mouse and human ETP-ALL to LSD1i-induced cell death both in vitro and in vivo.